Skip Ribbon Commands
Skip to main content

Dr Tang Pooi Ling Tiffany

MBBS (Melbourne), MRCP (UK), M Med (Int Med), BMedSci (Melbourne)


National Cancer Centre Singapore

Specialty: Medical Oncology

Sub-specialties: Lymphoma

Conditions Treated by this Doctor:

Clinical Appointments

  • Consultant SingHealth Duke-NUS Blood Cancer Centre
  • Consultant Division of Medical Oncology National Cancer Centre SingaporeNational Cancer Centre Singapore

Academic Appointments

  • Assistant Professor
  • Senior Clinical Lecturer


Dr Tiffany Tang is a consultant with the Division of Medical Oncology who sub-specialises in treating patients with lymphoma.
She obtained her MBBS from the University of Melbourne, her Masters of Medicine (Internal Medicine) from the National University of Singapore and her Membership to the Royal College of Physicians from the United Kingdom. She trained as a medical oncologist at the National Cancer Centre Singapore and went on to pursue a clinical research fellowship in the field of lymphoma at the Weill Cornell Medical College, New York.
Dr Tang is passionate about finding better treatment for patients with lymphoma, especially T- and Natural-killer/T-cell lymphomas, by developing rationally designed clinical trials. For her research in T-cell lymphomas, she won the American Society of Clinical Oncology Merit Award in 2014 and was selected to participate in the prestigious American Society of Hematology Clinical Research Training Institute education and mentoring programme between 2014-2015. She is also a recipient of the National Medical Research Council Transition Award in 2018 for her work in developing better treatments for T-cell lymphoma. She is part of initiatives to develop centres of excellence for Hodgkin’s and B-cell lymphoma in Singapore.
Dr Tang is a clinical lecturer at the Yong Loo Lin School of Medicine and mentors students and junior doctors in their clinical training and research endeavours. She was the treasurer for the Singapore Society of Oncology from 2012-2013.


  • University of Melbourne, Australia, 2004, MBBS
  • University of Melbourne, Australia, 2004, BMedSci
  • Royal College of Physicians (Edinburgh), United Kingdom, 2009, MRCP
  • National University of Singapore, 2009, MMed
  • Singapore Medical Council, 2012, Specialist registration in Medical Oncology

Professional Appointments and Committee Memberships

  • Consultant, Division of Medical Oncology, National Cancer Centre Singapore
  • Assistant Professor, Duke-NUS School of Medicine
  • Senior Clinical Lecturer, Yong Loo Lin School of Medicine


  • 2018 National Medical Research Council, Transition Award
  • 2014 American Society of Hematology, Clinical Research Training Institute
  • 2014 American Society of Clinical Oncology Merit Award
  • 2013 Singhealth Human Manpower Development Programme
  • 2012 Singhealth Best Registrar Award
  • 2011 Singhealth Best Registrar Award
  • 2005 National Healthcare Group (NHG) Doctor Award NHG/Singhealth Combined Scientific Meeting

Publications and Research Trials

Selected Publications:
1.    Tang T, Khoo LP, Lim C, Ham HS, Kim SJ, Hong H, Phipps C, Lee, YS, Tao M, Quek R, Farid M, Lin TY, Kim WS, Lim ST. Outcomes of patients with peripheral T-cell lymphoma in first complete remission: data from three tertiary Asian cancer centers. Blood Cancer Journal 2017Blood Cancer J. 2017; 7(12):653
2.    Pera B*, Tang T*, Marullo R, Yang SN, Ahn H, Patel J, Elstrom R, Ruan J, Furman R, Leonard J, Cerchietti L, Martin P. Combinatorial epigenetic therapy in diffuse large B cell lymphoma pre clinical models and patients. Clin Epigenetics 2016; 8: 79 *co-first author
3.    Tang T, Chen Z, Praditsuktavorn P, Khoo LP, Ruan J, Lim ST, Tan D, Phipps C, Lee YS, Goh YT, Hwang W, Tao M, Quek R, Farid M, Furman RR, Leonard JP, Martin P. The role of surveillance imaging in patients with peripheral T-cell lymphoma.Clin Lymphoma Myeloma Leuk. 2016 Mar;16(3):117-21.
4.    Lee J, Chan A, Tang T. Tuberculosis reactivation in a patient receiving anti-programmed death-1 (PD-1) inhibitor for relapsed Hodgkin’s lymphoma. Acta Oncologica 2016 Apr;55(4):519-20.
5.    Li Z, Xia Y, Feng L-N, Li H-M, Cui J, Cai QQ, Sim KS, Nairismagi MJ, Laurensia Y, Meah WY, Liu WS, Guo YM, Chen LZ, Feng QS, Pang CP, Chen LJ, Chew SH, Ebstein RP, Foo JN, Liu J, Ha J, Khoo LP, Chin ST, Zeng YX, Aung T, Chowbay B, Diong CP, Zhang F, Liu YH, Tang T, ….Tan W, Peng R-J, Khor CC, Bei JX. Genetic risk of extranodal natural killer T-cell lymphoma: a genome-wide association study. Lancet Oncology 2016.
6.    M-L Nairismagi, J Tan, JQ Lim, S Nagarajan, CCY Ng, V Rajasegaran, D Huang, WK Lim, Y Laurensia, GC Wijaya, ZM Li, I Cutcutache, WL Pang, S Thangaraju, J Ha, LP Khoo, ST Chin, S Dey, G Poore, LHC Tan, HKM Koh, K Sabai, H-L Rao, KL Chuah, Y-H Ho, S-B Ng, S-S Chuang, F Zhang, Y-H Liu, T Pongpruttipan, YH Ko, P-L Cheah, N Karim, W-J Chng,T Tang, M Tao, K Tay, M Farid, R Quek, SG Rozen, P Tan, BT The, ST Lim, S-Y Tan, CK Ong. JAK-STAT and G-protein coupled receptor signalling pathways are frequently altered in epitheliotropic intestinal T-cell lymphoma. Leukemia 2016; 30: 1311-9
7.    Tang T, Martin P. Mantle cell lymphoma: Taking therapeutic advantage of new insights into the biology. Curr Hematol Malig Rep 2014; 9(3): 254-61
8.    Tang T, Martin P. When indolent follicular lymphoma is not indolent. Leukemia and Lymphoma 2014; 55(11): 2417-8
9.    Koo GC, Tan SY, Tang T, Poon SL, Allen G, Tan L, Chong SC, Ong WS, Ong, Tay K, Tao M, Quek R, Loong S, Yeoh KW, Yap SP, Lee KA, Lim LC, Tan D, Goh C, Cutcutache I, Yu WSS, Ng CC, Rajasegaran V, Heng HL, Gan A, Ong CK, Rozen S, Tan P, Teh BT, Lim ST.  Janus kinase 3 activating mutations identified in natural killer/T-cell lymphoma. Cancer Discovery 2012; 7: 591-7
10.  Chan A, Tang T, Ng T, Shih V, Tay K, Tao M, Quek R, Lim ST. To SMILE or not: supportive care matters. J Clin Oncol 2012; 30(9): 1015-6

Research Trials

  • A phase I Investigator Sponsored Trial of Selinexor (KPT-330), a Selective Inhibitor of Nuclear Export/Sine Compound and Ifosfamide, Carboplatin, Etoposide (ICE) in patients with relapsed or refractory peripheral T-cell lymphoma 
  • CHRONOS-1 (Bayer 16349 Part B) -Open-label, uncontrolled Phase II trial of intravenous PI3K inhibitor BAY 80-6946 in patients with relapsed, indolent or aggressive Non-Hodgkin’s lymphomas 
  • Bayer 17119 An open-label, single-arm Phase II study in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) to evaluate efficacy and safety of treatment with single agent copanlisib and the impact of biomarkers thereupon 
  • KCP-330-013 A Multi-centre, Phase II, Open-label Study of Efficacy and Safety of the Selective Inhibitor of Nuclear Export (SINETM) Selinexor (LPT-330) in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) and Cutaneous T-cell Lymphoma (CTCL)